Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the USA / NCT07677358
Recruiting Phase 1

A Study to Learn How the Study Medicine Called Atirmociclib is Handled by the Body in People With Normal Liver Function and Different Levels of Liver Disease

NCT07677358 · tracked via the Priya Life Science USA tracker
Sponsor
Pfizer
Phase
Phase 1
Started
2026-06-29
Last updated
2026-08-21

Condition(s) studied

Hepatic ImpairmentHealthy, Hepatic InsufficiencyHealthy Adults

Investigational drug(s) / intervention(s)

Atirmociclib →

Atirmociclib: atirmociclib administered as a single oral dose

Study summary

The purpose of this study to understand how the study medicine atirmociclib behaves in the body and how safe it is for people with different levels of liver health.

The study is seeking participants who are:

* Aged 18 years or older
* Have a BMI of 17.5 to 40 kg/m2, and body weight more than 50 kg.
* Have normal liver function or have stable mild, moderate, or severe liver disease

Participants will receive study medicine by mouth. Blood samples will be collected to see how much of the medicine is in the body over time. This will help understand whether liver disease changes how the medicine is handled.

Participants will be in the study for about 9 weeks. Those with normal liver function will stay in the clinic for about 7 days. People with liver disease will stay for about 9 days. After leaving the clinic, people may be contacted for follow-up. This may be done by phone or through a clinic visit.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion criteria including but not limited to: * BMI of 17.5-40 kg/m2; and a total body weight \>50 kg (110 lb). * Willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures. * Capable of giving signed informed consent. Normal hepatic function group only: \- Overtly healthy as determined by medical evaluations including medical history, physical examination, laboratory tests, vital signs and standard 12-lead ECGs. Hepatic impairment groups only: \- Stable hepatic impairment meeting the criteria for Child-Pugh Class A, B, or C . Stable hepatic impairment is defined as no clinically significant change in disease status within the last 28 days prior to the screening visit, as documented by the participant's recent medical history. Exclusion criteria including but not limited to: * Any condition or history of surgery possibly affecting drug absorption. * Use of prohibited prior or concomitant medications. Normal hepatic function group only: \- Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing). Hepatic impairment groups only: \- A diagnosis of hepatic dysfunction secondary to any acute ongoing hepatocellular process that is documented by medical history, PE, liver biopsy, hepatic ultrasound, CT scan, or MRI.

Primary outcome measure(s)

  • Maximum Observed Plasma Concentration (Cmax) for atirmociclib in participants with normal hepatic function — Pre-dose and at, 1, 2, 4, 6, 8, 12, and 24, 36, 48, 60, 72, 96, 120, 144 hours after a single oral dose
    Maximum observed plasma concentration (Cmax) for atirmociclib following a single oral dose in participants with normal hepatic function
  • Maximum Observed Plasma Concentration (Cmax) for atirmociclib in participants with hepatic impairment — Pre-dose and at, 1, 2, 4, 6, 8, 12, and 24, 36, 48, 60, 72, 96, 120, 144, 168, 192 hours after a single oral dose
    Maximum observed plasma concentration (Cmax) for atirmociclib following a single oral dose in participants with hepatic impairment
  • Area under the curve from time zero to extrapolated infinite time [AUC (0 - ∞)] for atirmociclib in participants with normal hepatic function — Pre-dose and at, 1, 2, 4, 6, 8, 12, and 24, 36, 48, 60, 72, 96, 120, 144 hours after a single oral dose
    AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).
  • Area under the curve from time zero to extrapolated infinite time [AUC (0 - ∞)] for atirmociclib in participants with impaired hepatic function — Pre-dose and at, 1, 2, 4, 6, 8, 12, and 24, 36, 48, 60, 72, 96, 120, 144, 168, 192 hours after a single oral dose
    AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).

Trial sites (3)

FacilityCityRegionStatus
Floridian Clinical Research Miami Lakes Florida Recruiting
Orlando Clinical Research Center Orlando Florida Recruiting
Genesis Clinical Research Tampa Florida Recruiting

More Pfizer trials in the USA

A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer Active, not recruiting
Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC Recruiting
Real-World Effectiveness of Ritlecitinib in Alopecia Areata Patients in the US: A Retrospective Analysis Using EHR and Claims Data Active, not recruiting
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients Recruiting
A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS. Active, not recruiting

Other trials for the same condition

Phase 1a Single Ascending Dose Study of MIB-725 in Healthy Adults Recruiting
A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234 Recruiting
Pilot Study of the Entarik System With Advanced Functionality in Health Adults Recruiting
A Study to Test How BI 1291583 is Taken up in the Blood of People With and Without Liver Problems Recruiting
A Study to Test How BI 3000202 is Taken up in the Blood of People With and Without Liver Problems Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07677358 on ClinicalTrials.gov ↗ ← All trials in the USA